Elutia Inc. (ELUT)
Elutia Inc. (ELUT) Stock Price, Analysis & Data
| Bid | 0.56 |
| Market Cap | 37.42M |
| Revenue (ttm) | 12.46M |
| Net Income (ttm) | -21.88M |
| Beta | 0.88 |
| EPS (ttm) | -0.65 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.77 |
| P/B (ttm) | 1.66 |
| P/S (ttm) | 3.00 |
| Earnings Date | Aug 13, 2026 |
| Ask | 1.06 |
| Volume | 10,874 |
| Avg. Volume (20D) | 90,101 |
| Open | 0.82 |
| Previous Close | 0.80 |
| Day's Range | 0.78 - 0.86 |
| 52-Week Range | 0.50 - 2.50 |
| Analyst | n/a |
| Price Target | 5 (488.24%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ELUT
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tis...
Financial Performance
In 2025, Elutia's revenue was 12.29M, a decrease of -15.03% compared to the previous year's 14.47M. Earnings were 53.38M, a decrease of -198.95%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for ELUT stock is "null". The 12-month stock price forecast is 5, which is upside of 488.24% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
